GlassScriptPhysician profile
Debabrata Sen
NPI 1629012539
$3,834.68
in general payments reported to CMS, 2019-2025
23 companies · $571 in 2025
The $571 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $608 · 2021: $609 · 2022: $345 · 2023: $315 · 2024: $701 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $858.10 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $541.56 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $509.92 | 2019-2024 | Xarelto |
| Abbvie INC. | $346.29 | 2021-2025 | Dalvance, Avycaz |
| E.R. Squibb & Sons, L.L.C. | $291.22 | 2019-2023 | Eliquis |
| Pfizer INC. | $283.62 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.99 | 2019-2020 | |
| Amgen INC. | $124.99 | 2020 | |
| Glaxosmithkline, LLC. | $108.47 | 2019 | |
| Merck Sharp & Dohme LLC | $102.50 | 2021-2024 | Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $75.73 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $64.15 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $59.50 | 2024-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $47.01 | 2024 | Mounjaro, Zepbound |
| Abbott Laboratories | $31.43 | 2025 | Cardiomems |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.36 | 2019-2024 | Xifaxan, Trulance |
| Biogen, INC. | $22.77 | 2020 | |
| Global Blood Therapeutics, INC. | $22.73 | 2021 | |
| Philips North America LLC | $19.23 | 2020 | |
| Eisai INC. | $18.57 | 2022 | |
| Genzyme Corporation | $18.18 | 2019 | |
| Allergan, INC. | $18.15 | 2019 | |
| Exact Sciences Corporation | $14.21 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debabrata Sen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.